Genprex (NASDAQ: GNPX) is a clinical-stage,
gene-therapy company focused on the advancement of its lead drug candidate,
Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for
non-small cell lung cancer (“NSCLC”). An article discussing the company reads,
“Oncoprex is designed to interrupt cell signaling pathways that cause replication
and proliferation of cancer cells, to target and kill cancer cells via receptor
pathways, and to stimulate natural immune responses against cancer. Oncoprex
consists of the TUSC2 tumor suppressor gene encapsulated in a positively
charged lipid nanoparticle. It is injected intravenously, specifically
targeting cancer cells, which generally have a negative electrical charge. Once
Oncoprex is taken up into a cancer cell, the TUSC2 gene is expressed in a
protein that is capable of restoring certain defective functions arising in the
cancer cell (http://ibn.fm/zkW0b).”
To view the full article, visit http://ibn.fm/IpS2N
About Genprex Inc.
Genprex is a clinical-stage, gene-therapy company developing
potentially life-changing technologies for cancer patients based upon a unique
proprietary technology platform, including Genprex’s initial product candidate,
Oncoprex immunogene therapy for non-small cell lung cancer (“NSCLC”). Genprex’s
platform technologies are designed to administer cancer-fighting genes by
encapsulating them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where they express
proteins that are missing or found in low quantities. Oncoprex has a multimodal
mechanism of action whereby it interrupts cell-signaling pathways that cause
replication and proliferation of cancer cells, re-establishes pathways for
apoptosis, or programmed cell death, in cancer cells, and modulates the immune
response against cancer cells. Oncoprex has also been shown to block mechanisms
that create drug resistance. For more information, visit the company’s website
at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment